Phacilitate Leaders World 

Advanced Therapies: Cost-effective but unaffordable?

Advanced Therapies: Cost-effective but unaffordable?

Episode three of the Phacilitate Leaders World super plenary sessions with Michael Meyers, Head of Investment Banking at T.R Winston & Company

"Most people's lifetime earnings do not reach the price of Kymriah"

Anthony Davies (otherwise known as our industry’s answer to Jeremy Paxman) probes Michael Meyers, Head of Investment Banking at T.R. Winston & Company, about how the astonishing prices of advanced therapies are going to be paid for and how risk should be responsibly managed.

Assuming quality-adjusted life years are sufficient, what approaches will be feasible and effective? Michael outlines his three ideas:

 

  • The capital market, private sector and public sector need to work together – a combination of a structured financial approach that will be attractive to pension funds, hedge funds etc.; forming risk pools amongst different payers and a government backstop
  • Value-based pricing – what if the next advanced therapy is not curative, what is the impact and value? If a treatment can take a young boy from DMD to BMD, while it’s not curative it is a huge advance
  • Reinsurance – there are companies that reinsure risk from catastrophic risk to manufacturing sites and other property

 

Michael and Anthony go on to discuss amortised payments, securitisation of risk and jedi mind tricks…

Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
    EUFETS GmbH
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
    Dendreon
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman
    GSK